• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    11/14/24 7:53:54 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRBU alert in real time by email
    SC 13G/A 1 p24-3175sc13ga.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Caribou Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    142038108

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 142038108

    13G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,235,225 (including 100,000 shares of Common Stock issuable upon exercise of options)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,235,225 (including 100,000 shares of Common Stock issuable upon exercise of options)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,235,225 (including 100,000 shares of Common Stock issuable upon exercise of options)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.5%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 142038108

    13G/APage 3 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,235,225 (including 100,000 shares of Common Stock issuable upon exercise of options)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,235,225 (including 100,000 shares of Common Stock issuable upon exercise of options)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,235,225 (including 100,000 shares of Common Stock issuable upon exercise of options)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.5%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 142038108

    13G/APage 4 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Biotech Private Investments, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    474,067

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    474,067

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    474,067

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.5%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 142038108

    13G/APage 5 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Differentiated Ventures Investments, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    474,067

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    474,067

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    474,067

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.5%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 142038108

    13G/APage 6 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    72 Investment Holdings, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    474,067

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    474,067

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    474,067

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.5%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 142038108

    13G/APage 7 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,709,292 (including 100,000 shares of Common Stock issuable upon exercise of options)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,709,292 (including 100,000 shares of Common Stock issuable upon exercise of options)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,709,292 (including 100,000 shares of Common Stock issuable upon exercise of options)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 142038108

    13G/APage 8 of 10 Pages

     

    Item 1(a). Name of Issuer.
      Caribou Biosciences, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      2929 7th Street, Suite 105, Berkeley, California 94710.

     

    Item 2(a). Name of Person Filing.
     

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Common Stock”), of the Issuer held by (and underlying options held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to shares of Common Stock held by (and underlying options held by) an investment fund managed by Point72 Asset Management; (iii) Point72 Biotech Private Investments, LLC (“Point72 Biotech”) with respect to shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC (“Differentiated Ventures”), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC (“72 Investment Holdings”), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen (“Mr. Cohen”) the sole member of 72 Investment Holdings and sole shareholder of Point72 Capital Advisors Inc., with respect to shares of Common Stock held by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings.

     

    Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Ltd. and Point72 Asia (Singapore) Pte. Ltd. are advisors under common control with Point72 Asset Management, and each acts as a sub-advisor with respect to a portion of the Common Stock reported herein.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.0001 per share.

     

    Item 2(e). CUSIP Number.
      142038108

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.
       
         

     

     

    CUSIP No. 142038108

    13G/APage 9 of 10 Pages

     

    Item 4. Ownership.
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on September 30, 2024.

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to securities held by an investment fund it manages. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management, and Point72 Capital Advisors Inc.

     

    Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner.

     

    The filing of this statement should not be construed as an admission that any of the foregoing persons or any reporting person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      See Item 2(a).

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 142038108

    13G/APage 10 of 10 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title: Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      POINT72 BIOTECH PRIVATE INVESTMENTS, LLC
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      DIFFERENTIATED VENTURES INVESTMENTS, LLC
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      72 INVESTMENT HOLDINGS, LLC
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

    Get the next $CRBU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRBU

    DatePrice TargetRatingAnalyst
    6/3/2024$13.00 → $3.00Outperform → In-line
    Evercore ISI
    11/8/2023Neutral
    Cantor Fitzgerald
    10/31/2023$13.00Outperform
    Evercore ISI
    7/11/2023$23.00Buy
    Truist
    2/18/2022$22.00Outperform
    RBC Capital
    2/14/2022$19.00Buy
    Brookline Capital
    12/1/2021$36.00Outperform
    Oppenheimer
    11/30/2021$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $CRBU
    Financials

    Live finance-specific insights

    See more
    • Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

      -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

      6/2/24 7:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

      -- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5:00 pm ET -- BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t

      4/4/24 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

      -- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date -- -- LBCL patient subgroup had a 50% CR rate at ≥6 months; 18 months is the longest LBCL subgroup CR maintained to date -- -- Actively enrolling second-line LBCL patients in ANTLER dose expansion -- -- Conference call and webcast scheduled for today at 4:30 pm ET -- BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-s

      7/13/23 4:01:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

      SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      12/6/24 4:06:56 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

      SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      11/14/24 7:53:54 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

      SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      11/14/24 6:08:51 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      3/17/25 8:01:22 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Ryali Sriram bought $24,651 worth of shares (17,360 units at $1.42) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      1/30/25 4:02:12 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

      BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transforma

      5/28/25 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its lead oncology clinical programs CB-010 and CB-011 with data disclosure for each planned for H2 2025. "Caribou's two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for

      5/8/25 4:05:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

      BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing trans

      5/6/25 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    SEC Filings

    See more
    • Caribou Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

      6/13/25 4:02:09 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Caribou Biosciences Inc.

      EFFECT - Caribou Biosciences, Inc. (0001619856) (Filer)

      5/15/25 12:15:15 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Caribou Biosciences Inc.

      DEFA14A - Caribou Biosciences, Inc. (0001619856) (Filer)

      5/8/25 5:05:27 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      3/17/25 8:01:22 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Haurwitz Rachel E. was granted 136,750 shares, increasing direct ownership by 86% to 295,450 units (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      2/21/25 8:21:07 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Albertson Tina M. was granted 14,589 shares (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      2/21/25 8:20:34 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Leadership Updates

    Live Leadership Updates

    See more
    • Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

      BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz

      1/2/25 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

      -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

      8/12/24 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

      -- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

      7/9/24 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Caribou Biosciences downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

      6/3/24 7:23:52 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Caribou Biosciences

      Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

      11/8/23 7:19:33 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Caribou Biosciences with a new price target

      Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

      10/31/23 8:58:42 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care